What prospects for leading regions and countries?Developments worldwide will influence the market from 2013, especially improving clinical research in developing countries. There exist many opportunities for pharmaceutical companies and contract research providers. See outlooks for clinical testing. You get individual forecasts to 2023 for 12 national markets and two regional groups, finding overall revenues:• US• Japan• Western Europe• Central and Eastern Europe (CEE)• Germany, France, UK, Italy and Spain (EU5)• Brazil, Russia, India and China (BRIC nations) and South Korea. Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues. What affects clinical trial services from 2013? Our report discusses issues and events affecting that industry and market from 2013: • Future of outsourced phase I, II and III trials and post-marketing studies • Demand from pharmaceutical and biopharma companies • Regulatory policy • Challenges in developed and developing countries • Adaptive trial designs and focus on late-stage R&D pipeline candidates • Patient recruitment and retention. Also, we discuss these aspects of the field:• Social media as tools for engaging patients• Technological progress for more-efficient trials• Sharing of risk between the pharma industry and CROs• CRO consolidation, specialisation and globalisation• Studies on orphan diseases• Biomarkers in drug development. See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks. Leading companies and 2015 market value We predict that the overall world market for clinical trial services will reach $30.6bn in 2015, and expand further to 2023. That outsourcing segment holds great potential for investment, development and revenue growth from 2013. You see how it will progress. We review 15 leading companies, including these:• Quintiles• Covance• PPD• Parexel International• ICON• INC Research• inVentiv Health.